Gene or Genome – Page 16

Merck & Co., Daiichi Sankyo Strengthen Partnership with New DLL3 Cancer Drug Agreement

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3, DLL3 gene, Immunostimulating conjugate (antigen), Merck & Co., MK-6070, Neoplasms, Neurosecretory Systems, Oncology Pipeline, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck & Co., Daiichi Sankyo, DLL3, T-cell engager, MK-6070, small cell lung cancer, neuroendocrine tumors, antibody-drug conjugates, oncology pipeline

Mallinckrodt to Sell Therakos Business Unit to CVC Capital for $925 Million

9 months ago talkbio0Tagged Capital Partners, central venous catheter (CVC) sets, Extracorporeal, Healthcare services, Immunotherapy, Lymphoma, T-Cell, Cutaneous, mallinckrodt, medical technology, Photopheresis, RNASE3 gene, Therakos

Mallinckrodt, Therakos, CVC Capital Partners, photopheresis, extracorporeal photopheresis, ECP, cutaneous T-cell lymphoma, CTCL, immunotherapy, pharmaceuticals, medical technology, healthcare services

Merck and Daiichi Sankyo Collaborate to Develop T-Cell Engager MK-6070 from Harpoon Acquisition

9 months ago talkbio0Tagged Antibody-Drug, Daiichi, DLL3 gene, Harpoon, Immunostimulating conjugate (antigen), Merck, MK-6070, Sankyo, Small cell carcinoma of lung, T-Lymphocyte

Merck, Daiichi Sankyo, T-cell engager, MK-6070, Harpoon Therapeutics, small cell lung cancer, DLL3, antibody-drug conjugates

Bristol Myers Squibb Terminates $1.6 Billion Deal, Returns TIGIT Rights to Agenus

9 months ago talkbio0Tagged Agenus, Dosage Forms, licensing agreement, Myers, squibb, TIGIT gene

Bristol Myers Squibb, Agenus, TIGIT, licensing agreement, pharmaceutical deal

Biotech Startup Airna Secures $60M to Advance RNA-Editing Therapy for Alpha-1 Antitrypsin Deficiency

9 months ago talkbio0Tagged ADAR gene, Airna, alpha 1-Antitrypsin Deficiency, Alpha-1, Antitrypsin Deficiency, Clustered Regularly Interspaced Short Palindromic Repeats, Genetic Medicine, RNA Editing, RNA therapy, startup

Airna, RNA editing, alpha-1 antitrypsin deficiency, AATD, biotech startup, genetic medicine, ADAR, CRISPR, RNA therapy

FDA Criticizes Brittany Mahomes’ Paid Instagram Post for Kaléo’s Auvi-Q

9 months ago talkbio0Tagged Advertisements, ANOS1 gene, Auvi-Q, Brittany Mahomes, pharmaceutical marketing, Social Media, United States Food and Drug Administration

FDA, Brittany Mahomes, Kaléo, Auvi-Q, misleading advertisement, social media regulation, pharmaceutical marketing

BioNTech-Regeneron vs. Moderna-Merck.Cancer Vaccine and PD-1 Inhibitor Combinations.

9 months ago talkbio0

, BioNTech, Regeneron, Moderna, Merck, Cancer Vaccine, PD-1 Inhibitor, mRNA Technology, Melanoma, Immunotherapy, Clinical Trials,

Incyte Reports Positive Results for PD-1 Inhibitor Zynyz in Two Phase 3 Clinical Trials

9 months ago talkbio0Tagged Carcinoma of anal margin, Incyte, Inhibitor, Non-Small Cell Lung Carcinoma, PDCD1 gene, Phase 3, Zynyz

Incyte, Zynyz, PD-1 Inhibitor, Phase 3 Clinical Trials, Squamous Cell Anal Carcinoma, Non-Small Cell Lung Cancer

BioNTech and Regeneron Achieve Significant Response Rate Success in Phase 2 Trial for mRNA Cancer Immunotherapy BNT111

9 months ago talkbio0Tagged BioNTech, Cancer Therapeutic Procedure, cemiplimab, checkpoint inhibitor, melanoma, mRNA immunotherapy, mRNA-LPX technology, PDCD1 gene, Phase 2 trial, Regeneron, Tetravalent RNA-lipoplex Cancer Vaccine BNT111, uridine

BioNTech, Regeneron, mRNA immunotherapy, BNT111, Phase 2 trial, melanoma, cancer treatment, PD-1 checkpoint inhibitor, cemiplimab, FixVac platform, uridine mRNA-LPX technology

Ventyx Abandons TYK2 Inhibitor Development Following Phase II Failure in Crohn’s Disease

9 months ago talkbio0Tagged Biosciences, Crohn 's disease, Drug Development, Failure (biologic function), Inhibitor, Phase 2 Clinical Trials, TYK2 gene, Ventyx, VTX958

Ventyx Biosciences, TYK2 inhibitor, VTX958, Crohn’s disease, Phase II trial, drug development failure